Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORESITE: Seizure Forecasting and Preventative Therapy in Drug-Resistant Epilepsy
NCT07012148Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of diazepam nasal spray in epilepsy, sponsored by Mayo Clinic. Primary endpoints: Safety and Adverse Events at 12 months, Safety - Cardiorespiratory Events at 12 months and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
diazepam nasal spray
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT07012148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012148.